Keros Therapeutics (KROS)10% owner bought ~$5.17M

~$5.17M

Approx. value · 500K sh @ $10.33

4.32M

Holds after · shares reported

Traded

Apr 9, 2025

Filed

Apr 12, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Apr 9, 2025 · this disclosureInsider10% owner purchased ~$5.17M of KROS shares in the open market

What came next

1. Apr 9, 2025Insider · 1 personInsiders: 4 purchases (~$4.3M)

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Keros Therapeutics

For Keros Therapeutics, OQRO holds 6 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its KROS page.

Other recent filings by ADAR1 Capital Management, LLC, 10% owner

• SEC Form 4 at Inmed Pharmaceuticals (INM)Oct 8, 2026
• SEC Form 4 at Inmed Pharmaceuticals (INM)Oct 8, 2026
• SEC Form 4 at Inmed Pharmaceuticals (INM)Oct 8, 2026
• SEC Form 4 at Inmed Pharmaceuticals (INM)Oct 6, 2026
• SEC Form 4 at Inmed Pharmaceuticals (INM)Oct 6, 2026

The full history of ADAR1 Capital Management, LLC, 10% owner is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Keros Therapeutics

• SEC Form 4Aug 20, 2026
• SEC Form 4Aug 20, 2026
• SEC Form 4Aug 20, 2026
• SEC Form 4Aug 20, 2026
• SEC Form 4Aug 19, 2026
• SEC Form 4Jul 17, 2026

Everything OQRO holds on this company is on its KROS page.